Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:RGC 25 September 2025 - 7 October 2025

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Regencell Bioscience shares soared over 64,000% in 2025, peaking at $83.60 before plunging 74% to around $17–18 by October, with a market cap near $8.5 billion. The stock jumped again in early October after S&P Global BMI Index inclusion and positive Phase II trial data showing a 37% improvement in ADHD/ASD symptoms. Regencell remains unprofitable with no revenue. Analysts maintain a “Strong Sell” rating.
7 October 2025
··
Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

Regencell Bioscience (RGC) stock soared over 82,000% in 2025, peaking at $83.60 before plunging 74% after a 38-for-1 stock split and speculative trading frenzy. The Hong Kong biotech, which has no revenue and focuses on Traditional Chinese Medicine for neurocognitive disorders, now trades near $17 with an $8.5 billion market cap. Regulators halted trading multiple times amid extreme volatility.
4 October 2025
·
RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

Regencell Bioscience (RGC) shares closed at about $14.50 on September 25, 2025, up over 10,000% year-to-date despite no approved products or revenues. The company, valued at $7.3 billion, remains pre-revenue and posted a $4.4 million loss in 2024. RGC’s stock saw a 38-for-1 split in June and is controlled mostly by insiders, with only 30.5 million shares publicly traded. The stock’s surge has drawn regulatory scrutiny over volatility and market manipulation risks.
25 September 2025
·
1 2

Stock Market Today

  • Tourmaline Oil Issues CA$250 Million 2031 Notes: Investor Implications
    March 22, 2026, 5:03 AM EDT. Tourmaline Oil Corp. raised CA$250 million through senior unsecured notes due 2031, with a fixed 3.934% coupon and a provisional BBB (High) credit rating. The proceeds aim to refinance debt and fund general corporate needs, aligning with its CA$1.75 billion net debt target and balance sheet discipline. While extending debt maturities supports Tourmaline's long-term capital strategy, investors must monitor risks from its heavy natural gas exposure and significant Montney and LNG-linked project spending. The notes fit into a broader investment narrative centered on steady growth, capital control, and cash flow resilience amid fluctuating gas prices. Current fair value estimates cluster between CA$67.04 and CA$72.00, reflecting cautious optimism about the company's funding flexibility and long-term prospects.
Go toTop